AstraZeneca update on Fasenra PIII trial in COPD
11 May 2018 07:00 BST AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease GALATHEA Phase III trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD Second Phase III trial TERRANOVA is ongoing with results expected later this quarter AstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic